Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Forstpointner R, et al. Among authors: hanel a. Blood. 2004 Nov 15;104(10):3064-71. doi: 10.1182/blood-2004-04-1323. Epub 2004 Jul 29. Blood. 2004. PMID: 15284112 Free article. Clinical Trial.
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Forstpointner R, et al. Among authors: hanel a. Blood. 2006 Dec 15;108(13):4003-8. doi: 10.1182/blood-2006-04-016725. Epub 2006 Aug 31. Blood. 2006. PMID: 16946304 Free article. Clinical Trial.
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W. Forstpointner R, et al. Among authors: hanel a. Dtsch Med Wochenschr. 2002 Oct 25;127(43):2253-8. doi: 10.1055/s-2002-35017. Dtsch Med Wochenschr. 2002. PMID: 12397539 Clinical Trial. German.
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR. Hänel M, et al. Among authors: hanel a. Ann Hematol. 2000 Jun;79(6):304-11. doi: 10.1007/s002779900150. Ann Hematol. 2000. PMID: 10901609 Clinical Trial.
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M; East German Study Group Hematology/Oncology (OSHO); Study Alliance Leukemia (SAL). Thiel A, et al. Among authors: hanel m, hanel a. Ann Oncol. 2015 Jul;26(7):1434-40. doi: 10.1093/annonc/mdv205. Epub 2015 Apr 28. Ann Oncol. 2015. PMID: 25922062 Free article. Clinical Trial.
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: hanel m, hanel a. J Cancer Res Clin Oncol. 2022 May;148(5):1171-1181. doi: 10.1007/s00432-021-03702-7. Epub 2021 Jun 26. J Cancer Res Clin Oncol. 2022. PMID: 34176014 Clinical Trial.
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK, Benner A, Bertsch U, Brossart P, Hänel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H. Mai EK, et al. Among authors: hanel a. Br J Haematol. 2016 Jun;173(5):731-41. doi: 10.1111/bjh.13994. Epub 2016 Mar 17. Br J Haematol. 2016. PMID: 26990892 Free article. Clinical Trial.
59 results